# A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

> **NCT03017820** · PHASE1 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 127 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma
- Histiocytic and Dendritic Cell Neoplasm
- Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Plasma Cell Myeloma
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent T-Cell Non-Hodgkin Lymphoma
- Refractory Acute Myeloid Leukemia
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Angioimmunoblastic T-Cell Lymphoma
- Refractory Mycosis Fungoides
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Plasma Cell Myeloma
- Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory T-Cell Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
- **PROCEDURE:** Single Photon Emission Computed Tomography
- **BIOLOGICAL:** Cemiplimab
- **DRUG:** Ruxolitinib
- **BIOLOGICAL:** ipilimumab
- **BIOLOGICAL:** Nivolumab
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Bone Marrow Aspiration

## Key facts

- **NCT ID:** NCT03017820
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-04-04
- **Primary completion:** 2028-12-31
- **Final completion:** 2032-04-01
- **Target enrollment:** 127 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03017820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03017820, "A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03017820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*